Which muscles hold their strength through weight loss? A gene hunt
A transcriptomic sub-study of the CALERIE calorie-restriction trial links 151 genes to preserved leg strength during weight loss, independent of how much body mass was lost.
Two obesity-diagnosis systems agree on advanced disease, split early
Applied to 411,000 UK Biobank adults, the Edmonton staging system and the Lancet Commission's clinical-obesity model classified severe disease alike but diverged on who counts as early-stage.
Higher pre-pregnancy weight tracks with offspring heart disease decades on
In 2.5 million Swedish births followed to adulthood, mothers' early-pregnancy obesity was linked to a stepwise rise in offspring cardiovascular disease, though sibling analyses temper the size.
Eighteen months, 14 new trials: the obesity-drug evidence base has doubled in size
An updated Annals review now covers 38 randomised trials and 25,816 people. Tirzepatide leads the marketed drugs at 19.0% placebo-subtracted weight loss; the experimental multiagonists run higher.
Indoor gyms near home tracked lower obesity in 164,649 Chinese preschoolers
The association was strongest where the air was worst — which is the tell. A parallel US survey finds the indoor facilities are the ones vanishing from low-income neighbourhoods.
MRI in 183 knees: running showed no cartilage damage. Obesity showed up clearly.
A matched study compared recreational runners, non-runners and adults with obesity, one triplet at a time. The first two groups were indistinguishable on structure and function. The third was not.
Eating late does change your metabolism. Whether it makes you fatter is less clear.
A tightly controlled crossover trial found late eating increased hunger, cut waking energy expenditure and shifted fat-tissue gene expression. The population data show a 17% higher odds of obesity.
Weight loss modifies some diseases and is untested in most of the ones it is blamed for
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
GLP-1 drugs cost roughly $1,000 a month and a few dollars to make
A study estimated semaglutide's class could be produced for under $75 a month; it lists near $1,000. The gap is patent protection, and in the US it runs to 2032.
FDA moves a diabetes trial's retinopathy data into Zepbound's obesity label
A supplement approved on 26 August adds SURPASS-CVOT to the prescribing information and rewrites the eye warning so it is addressed to patients with a history of retinopathy rather than to patients with diabetes.
In Tuvalu, secondhand smoke tracked with sleep apnoea more closely than smoking did
A 4,066-person survey series across Funafuti and the outer islands links second-hand smoke exposure — reported by 61% of participants — to obesity and elevated STOP-Bang scores.
Each 30 minutes of weekly aerobic exercise produced half a kilogram of weight loss
A meta-analysis of 116 randomised trials found weight, waist and body fat falling steadily up to 300 minutes a week. In one 24-week trial, 48% of participants compensated by about 308 kcal a day.
Australia may cut Wegovy from $5,000 a year to $25 a script, for a narrow group
PBAC recommended subsidized listing in November 2025 for adults with obesity and a history of heart attack or stroke. Price negotiations with Novo Nordisk had not concluded.
GLP-1s and lean mass: 2026 trials narrow the question without closing it
Pooled randomised data show incretin drugs shed lean mass in about the same proportion as lifestyle weight loss. The evidence gap is people who train seriously, and it has not been filled.
Sleep apnea now has a drug. New data show what it fixes and what it doesn't.
Tirzepatide has been approved for obstructive sleep apnea since December 2024. A January 2026 reanalysis of the trial behind that approval separates what weight loss fixed from what treating the breathing fixed.
Meta-analysis: protein supplements nudge cholesterol down in overweight adults, modestly
Pooling 32 trials, researchers found milk, whey, casein, and soy protein lowered LDL and total cholesterol slightly — but the effect shrank once weaker studies were excluded.
Removing one mitochondrial protein protected mice from diet-induced obesity
Mice lacking the chaperone GRPEL2 stayed leaner on a high-fat diet and kept better insulin sensitivity — an early mechanistic finding, not a treatment, and so far only in mice.
Diabetes prevalence in the Middle East and North Africa doubled in 33 years
New GBD analysis across 21 countries finds one group whose burden fell — children — while incidence rose 92% overall and the sex pattern inverted.
The first oral GLP-1 is approved. The needle was never the only barrier.
Orforglipron removes the injection from weight-loss medicine — a real change for people who refused one. Supply, cost, and coverage are the harder problems it does not solve.
Obesity and sleep disorders track with worse semen. Alcohol mostly does not.
An umbrella review graded 249 effect sizes across 67 risk factors for male infertility. More than half were rated very low certainty — and the review contradicts its own table on one of them.
A quarter of bariatric surgery candidates had no organ dysfunction — at the same BMI
Applying the clinical-versus-preclinical obesity framework to 2,316 surgical patients in four countries found two groups near-identical on BMI and different on almost everything else.
WHO called aspartame a possible carcinogen and left the safe intake unchanged
Two WHO bodies reported on the same day in July 2023 and reached findings that sound contradictory. Both were right, because they were answering different questions.
Breakfast is not the most important meal for weight. The trials point the other way.
Pooling 13 randomised trials, people assigned to eat breakfast ended up 0.44 kg heavier and ate 260 more calories a day than people assigned to skip it. The trials were small, short and mostly low quality.
The fat-burning zone is real, hard to measure, and not better than training harder
A 2026 meta-analysis of 19 trials found training at maximal fat-oxidation intensity cut body weight by 3.66 kg. Head-to-head trials against interval training find no consistent winner on body fat.
The mechanism FDA will use to restrict GLP-1 compounding is now on the record
In February, FDA said it intended to act against compounded GLP-1 supply without saying how. The answer arrived in May: exclude semaglutide, tirzepatide and liraglutide from the list.
Semaglutide and tirzepatide cut alcohol-related hospitalizations by up to 65%
Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.
262 trials, 19 drugs, one ranking: the BMJ compares the whole obesity-drug field
Tirzepatide topped weight loss at 14.9%. But only subcutaneous semaglutide showed a mortality benefit — and no drug moved the needle on quality of life or kidney failure.
Semaglutide users had 51% lower suicidal ideation risk than older GLP-1 users
Tirzepatide and semaglutide showed comparable psychiatric risk profiles against each other over two years. Against earlier GLP-1 drugs, semaglutide came out ahead on all three measures.
Cardiovascular burden fell for 20 years. US maternal mortality stayed an outlier.
A Global Burden of Disease comparison puts the 2023 US maternal mortality rate at 33.8 per 100,000 live births, alongside cardio-kidney-metabolic risk burdens several times those of other high-income countries.
Three obesity definitions, one population: prevalence ran from 17% to 38%
A Swiss cohort was classified by WHO, NIH and EASO criteria at the same time. The share of people with obesity roughly doubled, and the overweight category shrank to fill the gap.
Bariatric surgery still beats GLP-1 drugs on weight loss, 44,000 patients show
Gastric bypass patients lost roughly 28% of body weight at three years, against 7-11% for tirzepatide or semaglutide — even among patients who stayed on the drugs continuously for at least a year.
Across 11,220 patients in seven trials, orforglipron showed no signal for liver injury
Lilly's oral GLP-1 pill actually lowered liver enzymes on average, and its rate of serious liver-injury criteria matched placebo exactly — six cases in each group, none attributable to the drug.
Across 41 trials, tirzepatide cut the most fat, and the most lean mass
Pooling 2,906 participants, researchers ranked how antidiabetic drugs affect fat versus lean body mass. Exercise blunted liraglutide's muscle loss; metformin, insulin, and DPP4 inhibitors barely moved either measure.
A glucagon-GLP-1 dual agonist cleared its liver-fat endpoint in a 216-person phase 3
SYNCHRONIZE-MASLD reports 84.2% of survodutide patients hitting a 30% cut in liver fat at 48 weeks. The trial measured fat on MRI, not fibrosis on biopsy — which is where the harder question still sits.
In 160,000 nondiabetic adults, GLP-1 users had 41% lower obesity-linked cancer risk
The association held across most demographic subgroups, but not among Black patients, a gap the study doesn't explain. Two-year follow-up limits what it can say about longer-term risk.
44 studies find no consistent cardiometabolic harm from hormonal contraceptives
Pooling a decade of research on women with hypertension, diabetes and obesity, researchers found modest blood pressure and metabolic shifts only in select high-risk subgroups.
Europe's new heart plan rests on data showing a twofold mortality gap inside the continent
The ESC Atlas reports 68 million disability-adjusted life years and more than three million cardiovascular deaths a year, with middle-income countries carrying roughly double the mortality of high-income ones.
Twelve diet scores compared across menopause. Two separated from the rest.
In 38,283 nurses tracked through the transition, low-insulinemic and planetary-health eating patterns had the strongest associations with less weight gain. The average woman still gained 0.8 kg a year.
Ketoacidosis reports in non-diabetic GLP-1 users are climbing sharply
A five-year FAERS analysis found both semaglutide and tirzepatide carry disproportionate ketoacidosis signals in people without diabetes, with roughly three-quarters of reported cases requiring hospitalization.
Switched to a daily pill after injections, patients kept three-quarters of the loss
ATTAIN-MAINTAIN tested orforglipron as a maintenance therapy for people who'd already lost weight on tirzepatide or semaglutide. Those on placebo regained roughly half of what the pill preserved.
Global waist thresholds missed 87.5% of Qatari women with obesity by body fat
A Qatar Biobank analysis derived local cut-points and found WHO's standard numbers misclassified more than half of men and nearly half of women in the sample.
With no head-to-head trial, statisticians built one: tirzepatide edges oral semaglutide
No study has directly compared injectable tirzepatide with the new high-dose oral semaglutide pill. A statistical technique that adjusts across two separate trials estimates the gap.
GLP-1 drugs and hair loss: semaglutide and tirzepatide carry the clearest signal
Pooling 24 studies out of 133 screened, researchers found hair shedding tied to rapid weight loss more than to the drugs directly — and a pattern that hits women disproportionately.
Europe scanned 30,000 livers and found undiagnosed liver disease in 1.6%
The LiverScreen project ran transient elastography across nine countries, then sent everyone who screened positive to a hepatologist. The gap between the two numbers is the interesting part.
Egypt cured millions of hepatitis C. Its liver cancer problem did not go away
Two 2026 reviews describe the same handover: as the virus recedes, obesity-driven fatty liver disease is moving into the space it occupied — in a population where roughly 40% of screened adults met obesity criteria.
A real-world comparison finds tirzepatide beating semaglutide and liraglutide
A single-clinic retrospective study in Istanbul followed patients on all three drugs for 36 weeks. The ranking matches what randomized trials have shown — with liraglutide the least tolerated of the three.
Waist size carried a stronger cognitive signal than BMI in a Dutch cohort
In 3,873 middle-aged adults followed with repeated testing, waist-based categories of overweight and obesity showed larger effect sizes than BMI-based ones. The link to actual decline appeared only in men.
In eight European countries, obesity added hospital nights. Underweight added far more
A survey-based analysis of the European Health Interview Survey puts a price on Europe's obesity-related hospital use, and finds the strongest single association is not with obesity at all.
A Qatari genome study found 180 genes switched off in living, healthy adults
Sequencing 6,141 people turned high consanguinity into a research advantage: it produced natural human knockouts that population studies elsewhere almost never see.
Adding a muscle-preserving antibody to semaglutide pushed weight loss past 17%
Bimagrumab targets fat, not appetite. Paired with semaglutide in 507 adults with obesity, the combination out-performed either drug alone at 48 weeks — with its own separate set of side effects.
Two GLP-1 pills went head to head. One won on blood sugar and lost on side effects.
ACHIEVE-3 randomised 1,698 people to orforglipron or oral semaglutide for 52 weeks. Orforglipron cut HbA1c more at every dose comparison — and produced more side effects and more dropouts.
GLP-1 drugs alongside progestins tracked with lower endometrial cancer risk
A 444,000-patient records study found a two-thirds lower rate of endometrial cancer when GLP-1 receptor agonists were added to progestin therapy. The two groups differed by eight years in average age.
About one in ten infection deaths worldwide may be attributable to obesity
A Lancet study across 547,000 adults and 925 infectious diseases finds obesity raises the risk of severe infection across almost every pathogen type. The global estimate rests on modelling, not on the cohorts themselves.
FDA says it will move against the ingredient supply behind mass-marketed compounded GLP-1s
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.
A six-month habit programme left more people in metabolic remission two years later
In a 618-person randomized trial, 27.8% of the intervention group met the sustained-remission endpoint at 24 months against 21.2% of comparators. The confidence interval nearly touches no effect.
Israel taxed sugary drinks for a year, then repealed it. Sales never fully recovered
Large taxed beverage sales fell 24 to 31 percent under the tax. In the period after repeal they remained 13 to 24 percent below pre-tax levels — and prices stayed elevated too.
After stopping obesity drugs, weight returns about four times faster than after a diet
An Oxford meta-analysis of 37 studies puts average regain at 0.4 kg a month across all weight-management drugs, and 0.8 kg a month for semaglutide and tirzepatide. Almost none of the newer-drug data runs past a year.
New US dietary guidelines raise protein, cap added sugar, and leave a fat problem
The 2025–2030 edition was released January 7. It is the first to name highly processed foods, and the first whose saturated-fat arithmetic does not obviously close.
They ate 500 fewer calories on unprocessed food. A reanalysis asks what they chose.
On the unprocessed diet, participants built plates 57% heavier and 110 calories lighter. The authors argue that fruit and vegetables were crowding out calories on purpose.
Do GLP-1 drugs get people off CPAP? A 74,000-patient emulation says: barely.
Matched against a comparator diabetes drug, incretin agonists were associated with an 8% lower rate of CPAP procedures — alongside a 32% lower mortality that should make readers cautious.
The first GLP-1 pill for weight management is approved. The interesting number is $149.
FDA cleared oral semaglutide 25 mg on 22 December for chronic weight management and cardiovascular risk reduction. Its self-pay price, not its efficacy, is what may distinguish it.
An app matched human coaches in a diabetes trial. Both worked about a third of the time.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
A triple agonist's first phase 3 readout: 28.7% weight loss, knee pain down three quarters
TRIUMPH-4 tested retatrutide in 445 adults with obesity and knee osteoarthritis. The weight numbers are striking. So are the discontinuation numbers sitting beside them.
Diabetes care's annual rulebook lands, and obesity medicine moves toward the centre of it
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
WHO issues its first global guideline on GLP-1 medicines for obesity
The recommendations are conditional, cover three drugs, and come with a projection that fewer than one in ten people who could benefit will have access by 2030.
Early-onset type 2 diabetes is rising fastest where incomes are lowest
Two November burden analyses put diabetes diagnosed before 40 on an upward path to 2050. In the Americas, Central Latin America carried the highest rates and men carried more of the burden than women.
Fitness at 18 tracked with sepsis risk decades later in a Swedish cohort
Nearly a million conscripts followed for three decades: obesity carried a 3.1-fold hazard for sepsis, and high cardiorespiratory fitness was associated with a 42% lower risk of dying from bacterial infection.
Orforglipron's diabetes trial lands below its obesity-only result
In ATTAIN-2, the highest dose of the oral GLP-1 pill cut body weight 9.6% over 72 weeks in adults with type 2 diabetes, against 11.2% in the earlier trial of adults without diabetes.
The Lancet's ultra-processed food series makes a displacement argument
Three papers published on 18 November argue the harm is not one ingredient but the replacement of whole-food diets. The evidence they assemble is strongest for diet quality and weakest where causation is hardest.
Two large real-world studies find little separating tirzepatide and semaglutide
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.
Sleep apnea was common in a Tanzanian cohort — and HIV was not the reason
Among 1,000 adults in Mwanza, overnight oximetry found sleep apnea in 17% of people with HIV and 19% without. Excessive daytime sleepiness, oddly, was more common in those without HIV.
Obesity from MC4R mutations came with lower cholesterol, not higher
Carriers of loss-of-function MC4R mutations had lower LDL and triglycerides than UK Biobank controls of similar adiposity, and lower cardiovascular risk. The brain sets body weight and lipids separately.
A triple dose of semaglutide bought about three more percentage points
Two phase 3b trials tested semaglutide 7.2 mg against the approved 2.4 mg dose. The extra weight loss was real but modest, and gastrointestinal side-effects and dysaesthesia rose alongside it.
Seventeen patients, one clinic: setmelanotide outside the trial setting
A French prospective cohort followed adults with rare genetic obesity treated with the MC4R agonist in routine care. Weight fell about 20% in the first year and hunger scores dropped 62%.
Cutting calories on top of a Mediterranean diet lowered diabetes risk by 31%
A Spanish trial in 4,746 adults compared an energy-reduced Mediterranean diet plus exercise against the same diet eaten freely. Over six years the absolute gap was 12.0% versus 9.5%.
Same healthy-eating guidance, two versions: the less processed one lost more weight
Fifty-five English adults ate two eight-week diets that both followed the UK Eatwell Guide. Both produced weight loss. The minimally processed version produced about one percentage point more.
Twenty-one trials of activity trackers found no blood pressure benefit
A meta-analysis of pedometer, tracker and smartwatch interventions lasting 12 to 48 weeks found no significant change in systolic or diastolic pressure — nor in weight, glucose or HbA1c.
99 trials of intermittent fasting: the differences between methods are small
A BMJ network meta-analysis of 6,582 adults finds alternate day fasting the only intermittent method that beat continuous calorie restriction — by 1.29 kg, mostly in short trials.